Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2009-08-25
2011-11-15
Badio, Barbara P (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
08058267
ABSTRACT:
The invention relates to compounds of formula (I):wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
REFERENCES:
patent: 4892868 (1990-01-01), Castagnola et al.
patent: 4921848 (1990-05-01), Frigerio et al.
patent: 5061701 (1991-10-01), Pellicciari et al.
patent: 5128481 (1992-07-01), Oda et al.
patent: 5175320 (1992-12-01), Pellicciari et al.
patent: 6200998 (2001-03-01), Sahoo et al.
patent: 6559188 (2003-05-01), Gatlin et al.
patent: 6639078 (2003-10-01), Haffner et al.
patent: 6777446 (2004-08-01), Houze
patent: 6906057 (2005-06-01), Forman et al.
patent: 6984650 (2006-01-01), Haffner et al.
patent: 6987121 (2006-01-01), Kliewer et al.
patent: 7138390 (2006-11-01), Pellicciari
patent: 2002/0094977 (2002-07-01), Robl et al.
patent: 2002/0120137 (2002-08-01), Houze et al.
patent: 2002/0132223 (2002-09-01), Forman et al.
patent: 2003/0130296 (2003-07-01), Bauer et al.
patent: 0101554 (1984-02-01), None
patent: 0124068 (1984-11-01), None
patent: 0135782 (1985-04-01), None
patent: 0186023 (1986-07-01), None
patent: 0312867 (1989-04-01), None
patent: 0393493 (1990-10-01), None
patent: 1137940 (2000-05-01), None
patent: 1140079 (2000-06-01), None
patent: 1536812 (2003-04-01), None
patent: 1378749 (2004-01-01), None
patent: 1165135 (2004-09-01), None
patent: 1473042 (2004-11-01), None
patent: 1568706 (2005-08-01), None
patent: 1185277 (2005-10-01), None
patent: 1947108 (2008-07-01), None
patent: WO-9728149 (1997-08-01), None
patent: WO-9731907 (1997-09-01), None
patent: WO-9736579 (1997-10-01), None
patent: WO-9802159 (1998-01-01), None
patent: WO-9938845 (1999-08-01), None
patent: WO 00/25134 (2000-05-01), None
patent: WO 00/37077 (2000-06-01), None
patent: WO-0040965 (2000-07-01), None
patent: WO 00/57915 (2000-10-01), None
patent: WO 00/76523 (2000-12-01), None
patent: WO-0130343 (2001-05-01), None
patent: WO 02/20463 (2002-03-01), None
patent: WO 02/064125 (2002-08-01), None
patent: WO-02072598 (2002-09-01), None
patent: WO-03015771 (2003-02-01), None
patent: WO-03015777 (2003-02-01), None
patent: WO-03016280 (2003-02-01), None
patent: WO-03016288 (2003-02-01), None
patent: WO 03/030612 (2003-04-01), None
patent: WO-03043581 (2003-05-01), None
patent: WO 03/080803 (2003-10-01), None
patent: WO 03/086303 (2003-10-01), None
patent: WO 03/090745 (2003-11-01), None
patent: WO-2004007521 (2004-01-01), None
patent: WO-2004048349 (2004-06-01), None
patent: WO-2005032549 (2005-04-01), None
patent: WO-2005082925 (2005-09-01), None
patent: WO-2005089316 (2005-09-01), None
patent: WO-2006122977 (2006-11-01), None
patent: WO-2008002573 (2008-01-01), None
patent: WO-2008091540 (2008-07-01), None
patent: WO-2010/059853 (2010-05-01), None
Mi, Li-Zhi et al. 2003. “Structural Basis for Bile Acid Binding and Activation of the Nuclear Receptor FXR.”Molecular Cell. vol. 11, pp. 1093-1100.
Pellicciari R. et al. 2002. “6alpha-Ethyl-Chenodeoxycholic Acid (6-EDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity.”J. Med. Chem. vol. 45, No. 17, pp. 3569-3572.
Souillac, et al. “Characterization of Delivery Systems, Differential Scanning Calorimetry.” (inEncyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Vippagunta et al. 2001. “Crystalline Solids.”Advanced Drug Delivery Reviewsvol. 48, pp. 3-26.
Aldini et al., “Relationship between structure and intestinal absorption of bile acids with a steroid or side-chain modification”,Steroids, 61(10):590-597 (1996).
Bishop-Bailey et al., “Expression and activation of the farnesoid X receptor in the vasculature”,Proc. Natl. Acad. Sci. U.S.A., 101(10):3668-3673 (2004).
Clerici et al., “Effect of Intraduodenal Administration of 23-Methyl-UDCA Diastereoisomers on Bile Flow in Hamsters”,Dig. Dis. Sci., 37(5):791-798 (1992).
Fiorucci et al., “The Nuclear Receptor SHP Mediates Inhibition of Hepaptic Stellate Cells by FXR and Protects Against Liver Fibrosis”,Gastroenterology, 127:1497-1512 (2004).
Forman et al., “Identification of a Nuclear Receptor that is Activated by Farnesol Metabolites”,Cell, 81:687-693 (1995).
Fukuchi et al., “5β-Cholane activators of the farnesol X receptor”,J. Steroid Biochem. Mol. Biol., 94(4):311-318 (2005).
Haslewood et al., “Specificity and some characteristics of a 7.alpha.-hydroxysteroid dehydrogenase fromE. coli”, Database accession No. 1978:419015.
Honorio et al., “Hologram QSAR Studies on Farnesoid X Receptor Activators”,Lett. Drug Des. Dis., 3(4):261-267 (2006).
Kihira et al., “Synthesis of sulfonate analogs of bile acids”,Steroids, 57(4):193-198 (1992).
Kim et al., “Hypocholesterolemic Effect of Bile Acid Sulfonate Analogs in Hamsters”,Biol.Pharm. Bulletin, 24(3):218-220 (2001).
Kliewer et al., “Peroxisome Proliferator-Activated Receptors: From Genes to Physiology”,Endo J., 56:239-263 (2001).
Mangelsdorf et al., “The RXR Heterodimers and Orphan Receptors”,Cell, 83:841-850 (1995).
Mikami et al., “Effect of some sulfonate analogues of ursodeoxycholic acid on biliary lipid secretion in the rat”,J. Lipid Res., 37(6)1181-1188 (1996).
Miki et al., “Sulfonate analogues of chenodeoxycholic acid: metabolism of sodium 3α, 7α-dihydroxy-25-homo-5β-cholane-25-sulfonate and sodium 3α, 7α-dihydroxy-24-nor-5β-cholane-23-sulfonate in the hamster”,J. Lipid Res., 33(11):1629-1637 (1992).
Nesto et al., “Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure”,Diabetes Care, 27(1):256-263 (2004).
Pellicciari et al., “Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structure-Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid”,J. Med. Chem., 47:4559-4569 (2004).
Pellicciari et al.,“Nongenomic Actions of Bile Acids. Synthesis and Preliminary Characterization of 23- and 6,23-Alkyl-Substituted Bile Acid Derivatives as Selective Modulators for the G-Protein Coupled Receptor TGR5”,J. Med. Chem., 50:4265-4268 (2007).
Raskin et al., “A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes”,Diabetes Care, 24(7):1226-1232 (2001).
Roda et al., “23-Methyl-3α, 7β-dihydroxy-5β-cholan-24-oic Acid: Dose-Response Study of Biliary Secretion in Rat”,Hepatol., 8(6):1571-1576 (1988).
Roda et al., “Bile acids with a cyclopropyl-containing side chain. IV. Physicochemical and biological properties of the four diastereoisomers of 3α,7β-dihydroxy-22,23-methylene-5β-cholan-24-oic acid”,J. Lipid Res., 28(12):1384-1397 (1987).
Rubin et al., “Combination Therapy With Pioglitazone and Insulin in Patients With Type 2 Diabetes”,Diabetes, 48(Suppl. 1):A110 (1999) (Abstract Only).
Sato et al., “Novel Potent and Selective Bile Acid Derivatives as TGR5 Agonists: Biological Screening, Structure-Activity Relationships, and Molecular Modeling Studies”,J. Med. Chem., 51(6):1831-1841 (2008).
Schmider et al., “Evidence for an additional sinusoidal bile salt transport system”, Database accession No. 2000:260886, Feb. 16, 2009.
Stenner et al., “The effect of ursodeoxycholic acid on fibrosis markers in alcoholic liver disease”,Flak Symposium, pp. 229-235 (2002).
Willson et al., “The PPARs: From Orphan Receptors to Drug Discovery”,J. Med. Chem., 43(4):527-550 (2000).
Liu, Y. et al., “Hepatoprotection by the Farnesoid X Receptor Agonist GW4064 in Rat Models of Intra- and Extrahepatic Cholestasis”,J. Clin. Invest., 112(11), 1678-1687 (2003).
Urizar, N.L. et al., A Natural Product that Lowers Cholesterol as an Antagonist Ligand for FXR,Science, 296(5573), 1703-1706 (2002).
Downes, M., et al.
Badio Barbara P
Elrifi, Esq. Ivor R.
Intercept Pharmaceuticals, Inc.
Loebach, Esq. Jennifer L.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Steroids as agonists for FXR does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Steroids as agonists for FXR, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Steroids as agonists for FXR will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4282468